Cystic fibrosis nursing: complete reference guide for students

Cystic fibrosis (CF) is a multisystem, autosomal recessive disease caused by mutations in the CFTR gene. An estimated 38,800 people were living with CF in the US in 2020, according to a CF Foundation registry analysis, and CF remains one of the most clinically complex conditions nursing students encounter – spanning pulmonology, gastroenterology, endocrinology, infectious disease, and transplant medicine. This reference covers the pathophysiology, pulmonary management, CFTR modulators, gastrointestinal care, infection control principles, and high-yield NCLEX testing points. CF is no longer simply a pediatric disease – the CFF Patient Registry’s 2025 highlights project that half of people with CF born in 2021–2025 will live to age 66 or beyond (with survival as much as two decades lower for people who are ineligible for CFTR modulators), meaning nurses across all settings will care for adults with CF. Use this alongside pediatric nursing reference, pneumonia nursing, and diabetes mellitus nursing for the clinical context this condition requires.

Pathophysiology

CFTR gene mutation and inheritance

CF results from mutations in the CFTR gene (cystic fibrosis transmembrane conductance regulator), located on chromosome 7. The CFTR protein functions as a chloride channel on epithelial cell surfaces. When this channel is absent, misfolded, or dysfunctional, chloride ions cannot move out of the cell normally. Sodium follows chloride; water follows sodium. The result is dehydrated, thick, viscous secretions in every organ system that lines its surfaces with mucus.

Inheritance is autosomal recessive: both parents must carry at least one mutated CFTR allele, and the child must inherit a mutated copy from each parent. Carriers (one functioning allele, one mutated) are phenotypically normal but can pass the mutation on. When two carriers have children, each pregnancy carries a 25% chance of CF, 50% chance of carrier status, and 25% chance of neither allele.

CFTR mutations

Over 2,000 CFTR mutations have been identified, grouped into six classes based on their mechanism of dysfunction. The most clinically significant mutations for nursing students are:

• ΔF508 (delta F508, F508del): The most common mutation by a wide margin. Keep the two figures distinct, because they are routinely confused: ΔF508 accounts for roughly 70% of CF alleles, while approximately 85% of people with CF in the US carry at least one ΔF508 allele (about 45% are homozygous). It causes the CFTR protein to misfold and be degraded before reaching the cell surface (class II: processing defect).
• G551D: A gating mutation (class III) – the protein reaches the cell surface but the channel fails to open. Responds to ivacaftor (Kalydeco).
• W1282X: A nonsense mutation producing a premature stop codon, resulting in little to no functional CFTR protein.
• N1303K: A processing defect mutation, less common than ΔF508 but clinically similar in presentation.

Mutation class determines which CFTR modulators are effective – a critical distinction in modern CF pharmacology.

Organ systems affected

Impaired chloride transport and dehydrated secretions affect multiple organ systems:

• Lungs (primary): Thick mucus obstructs airways, trapping bacteria and triggering chronic infection and inflammation. Progressive bronchiectasis (permanent airway dilation) develops over time. Pulmonary disease is the primary cause of morbidity and mortality in CF.
• Pancreas: Thick secretions block pancreatic ducts, causing autodigestion. Most CF patients have exocrine pancreatic insufficiency, leading to fat malabsorption and fat-soluble vitamin deficiency.
• GI tract: Thick intestinal secretions predispose to meconium ileus at birth and distal intestinal obstruction syndrome (DIOS) in older patients.
• Reproductive system: Males with CF have congenital bilateral absence of the vas deferens (CBAVD) – most are infertile. Females have reduced fertility due to thickened cervical mucus.
• Sweat glands: Defective chloride reabsorption in sweat ducts results in abnormally high sweat chloride – the basis of the diagnostic sweat chloride test.
• Liver: Biliary cirrhosis can develop from bile duct obstruction; less common than pulmonary and pancreatic complications.

Pulmonary manifestations and management

Obstructive lung disease

CF produces a chronic obstructive pattern on spirometry: reduced FEV1 (forced expiratory volume in one second), reduced FVC, and a normal or reduced FEV1/FVC ratio. Air trapping, hyperinflation, and bronchiectasis develop progressively over years. FEV1 percent predicted is the primary metric used to track disease progression and guide transplant referral.

Airway clearance therapy

Airway clearance is a cornerstone of CF management – performed daily regardless of symptoms and increased in frequency during pulmonary exacerbations. The goal is to mobilize thick mucus from peripheral airways so it can be expectorated or swallowed. The sequence matters. Cystic Fibrosis Foundation guidance runs: bronchodilator first, then the mucus thinner (hypertonic saline and/or dornase alfa), then airway clearance while the mucus is still thinned, then inhaled antibiotics last so they reach cleared airways.

Techniques include:

• High-frequency chest wall oscillation (HFCWO / vest therapy): An inflatable vest connected to an air-pulse generator delivers rapid chest wall compressions (5–25 Hz), loosening mucus from airway walls. Typically performed twice daily, 20–30 minutes per session.
• Autogenic drainage (AD): A breathing technique using controlled inspiration and expiration at different lung volumes to progressively move mucus from peripheral to central airways. Requires significant patient training but is device-independent.
• Active cycle of breathing technique (ACBT): Alternates breathing control, thoracic expansion exercises, and forced expiration technique (huffing) to mobilize and clear secretions.
• Postural drainage and percussion (PDP): Traditional gravity-assisted positioning combined with manual chest percussion. Less commonly used as the primary technique in adults but remains in use, particularly in pediatric and home care settings.

Bronchodilators and mucolytics

• Albuterol (short-acting beta-2 agonist): Given before airway clearance to open airways and maximize mucus mobilization. Do not skip this step – bronchospasm can occur with hypertonic saline in sensitized patients.
• Dornase alfa (Pulmozyme, DNase): A recombinant human DNase enzyme that cleaves extracellular DNA in CF sputum – DNA released from neutrophils killed during chronic infection dramatically increases sputum viscosity. Given via nebulizer, typically once daily. Administer before airway clearance so the mucus is thinned while it is being mobilized; it is not a bronchodilator and does not substitute for airway clearance.
• Hypertonic saline (7%): Draws water into the airway surface liquid by osmosis, rehydrating the mucus layer and improving mucociliary clearance. Given by nebulizer after bronchodilator. Can cause bronchospasm – pretreat with albuterol.

Chronic infection suppression

Chronic pulmonary infection has historically affected nearly everyone with CF. Common organisms progress in a predictable pattern:

• S. aureus (including MRSA) – common in early childhood
• Haemophilus influenzae – early respiratory colonizer
• Pseudomonas aeruginosa – dominant pathogen in adults; early first isolates can often be eradicated with inhaled tobramycin, but once chronic infection is established it is suppressed rather than cured

Chronic suppressive therapy for Pseudomonas aeruginosa includes:

• Inhaled tobramycin (TOBI): 28 days on, 28 days off, cycling indefinitely
• Azithromycin (250–500 mg three times weekly): Has anti-inflammatory and immunomodulatory properties beyond its antibiotic effect; reduces exacerbation frequency

Pulmonary exacerbation

A pulmonary exacerbation is an acute worsening of respiratory status requiring intensified treatment. Diagnostic criteria include increased cough, increased sputum production or change in sputum character, new or increased hemoptysis, increased dyspnea, fatigue, fever, anorexia and weight loss, and decline in FEV1 ≥10% from baseline.

Management requires IV antibiotics (selected by sputum culture and sensitivity), intensified airway clearance (up to four times daily), and nutritional support. Common IV antibiotic combinations target Pseudomonas (e.g., tobramycin + piperacillin-tazobactam, or ceftazidime + tobramycin). Courses typically run about 14 days. In the STOP2 trial, 10 days was noninferior to 14 for adults who improved early, and 21 days was no better than 14 for slower responders. See pneumonia nursing for context on nursing care during acute respiratory infections.

CFTR modulators

CFTR modulators are disease-modifying therapies that target the underlying protein dysfunction – not just the downstream consequences. They represent a fundamental shift in CF treatment over the past decade. However, they are mutation-specific and do not work for all patients.

Two warnings now apply across the whole class. All five current US labels (Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek) carry warnings for intracranial hypertension, added September 2025, and for serious neuropsychiatric events including anxiety, depression, sleep disturbance, and suicidal thoughts and behaviors, added March 2026. Ask about headache, visual changes, mood, and sleep at every visit for any patient on a modulator, not only those on Trikafta.

NCLEX tip 1: Trikafta improves CFTR function significantly but does not cure CF. Patients on Trikafta still require daily airway clearance therapy, PERT with meals, and routine monitoring. Discontinuing airway clearance after starting Trikafta is a common patient misconception – correct it proactively.

NCLEX tip 2: CFTR modulators work only for specific mutations. Ivacaftor works for gating mutations like G551D – it is ineffective in ΔF508 patients on its own because the protein never reaches the cell surface. The corrector must bring the protein to the surface before the potentiator has anything to act on.

The complex pharmacology of CFTR modulators and their CYP3A interactions make CF an excellent topic for pharmacology study guides and drug classification review.

Pancreatic and gastrointestinal management

Exocrine pancreatic insufficiency

Approximately 85–90% of CF patients have exocrine pancreatic insufficiency (EPI). Blocked pancreatic ducts prevent digestive enzymes from reaching the small intestine, causing:

• Fat malabsorption – steatorrhea (oily, foul-smelling stools), weight loss, failure to thrive in children
• Fat-soluble vitamin deficiency – vitamins A, D, E, and K are all affected (remember: ADEK). Vitamin K deficiency increases bleeding risk; vitamin D deficiency contributes to CF-related bone disease.
• Protein malabsorption – contributes to low muscle mass and impaired growth

Pancreatic enzyme replacement therapy (PERT)

PERT is prescribed by lipase units (not capsule count) per meal. Cystic Fibrosis Foundation guidance sets dosing at 500–2,500 lipase units per kilogram per meal, with a ceiling of 10,000 lipase units/kg/day and an alternative fat-based limit of 4,000 lipase units per gram of dietary fat per day. Doses above roughly 6,000 lipase units/kg/meal have been linked to fibrosing colonopathy in children under 12. Snacks require approximately half the meal dose.

Critical nursing and patient education points:

• PERT must be taken with food – not before sitting down, not after finishing the meal. The enzymes must mix with food in the stomach to be effective.
• Capsules can be opened and the beads mixed with acidic foods (applesauce, pureed fruit) for young children who cannot swallow capsules. Do not crush the beads.
• Fat-soluble vitamins (ADEK) are supplemented in water-miscible formulations – standard vitamin preparations are oil-based and poorly absorbed in EPI.

CF-related diabetes (CFRD)

CF-related diabetes affected approximately 20% of adolescents and 40–50% of adults with CF in the 2010 CFF/ADA guideline. In the modulator era, the 2025 CFF Registry reports about 7% of adolescents rising to nearly 40% of adults aged 40–49, and about a quarter of everyone aged 10 and older. It is distinct from type 1 and type 2 diabetes:

• Mechanism: Fibrosis progressively destroys pancreatic islet cells (both beta and alpha cells), causing insulin deficiency. Peripheral insulin resistance is less prominent than in type 2 diabetes.
• Treatment: Insulin is the recommended drug therapy (CFF/ADA guideline). Oral hypoglycemic agents are not recommended because they have not matched insulin’s effect on weight and lung function in CF. This is a critical distinction from type 2 diabetes management.
• Hypoglycemia: Less common than in type 1 or insulin-treated type 2 diabetes because residual alpha cell function (glucagon secretion) is partially preserved early in CFRD. However, tight control and missed meals can still cause hypoglycemia.
• Screening and monitoring: Screen with an annual 2-hour oral glucose tolerance test starting by age 10. HbA1c is not recommended as a screening test because it can read falsely low in CF; once CFRD is diagnosed, quarterly HbA1c and home glucose monitoring guide insulin therapy.
• Nutritional context: CF patients require 110–200% of normal daily caloric intake. A caloric-restricted diabetes diet appropriate for type 2 patients is dangerous in CF – never restrict calories in a CF-CFRD patient.

Refer to diabetes mellitus nursing for core insulin management principles, keeping in mind the CFRD-specific distinctions above.

Meconium ileus and DIOS

Meconium ileus – bowel obstruction from thick, inspissated meconium – occurs in approximately 20% of people diagnosed with CF and is often the first presentation of the disease. It presents as failure to pass meconium within 48 hours of birth, abdominal distension, and bilious vomiting. Because most meconium ileus occurs in infants with CF, any newborn with meconium ileus needs CF testing.

Distal intestinal obstruction syndrome (DIOS) is the older-patient equivalent – a partial or complete obstruction of the ileocecal region from inspissated intestinal contents. Presents with crampy right lower quadrant pain, abdominal fullness, and a palpable mass in the right iliac fossa. Management includes oral polyethylene glycol (PEG) solution, Gastrografin enema, or IV fluid hydration.

Infection control

Infection control in CF requires strict adherence to principles that go beyond standard precautions. The same respiratory pathogens that colonize one CF patient can be transmitted to another, causing devastating consequences.

Common organisms and clinical significance

Cohorting and segregation principles

CF patients must be kept apart from other CF patients. The CF Foundation/SHEA 2013 infection prevention guideline (Saiman) treats this as a safety standard. It is a CF-specific guideline, separate from the general CDC isolation tables. Specific requirements include:

• Minimal time in waiting areas: CF clinics should keep time in common waiting areas to a minimum through staggered schedules, pagers, and placing patients straight into an exam room, where they stay while the care team rotates in (the “room-to-room” model).
• One person with CF per event: Only one person with CF should attend any camp, educational retreat, or CF Foundation-sponsored indoor event (people with CF who live in the same household are the exception). Gatherings of CF patients carry documented transmission risk, particularly for Pseudomonas and Burkholderia.
• No shared nebulizers or airway clearance equipment: Device-sharing between CF patients is prohibited.
• Six-foot rule and masks: Every person with CF, regardless of culture results, should stay at least 6 feet (2 meters) from other people with CF in all settings (household members excepted) and wear a surgical mask in common areas of health care facilities.
• Single rooms: Hospitalized CF patients should be in single rooms. Patients with Burkholderia cepacia complex or M. abscessus need the strictest separation from other CF patients.

Health care personnel should use contact precautions (gown and gloves) for every person with CF, regardless of respiratory culture results – the CFF/SHEA 2013 guideline does not limit them to patients with known Pseudomonas, MRSA, or Burkholderia. The same guideline recommends against universal mask use by health care workers; the mask rule applies to the person with CF. Outside CF care, the general CDC rule differs: Appendix A gives Contact Precautions for MRSA and other MDROs only where the facility’s infection control program designates them, and it has no Droplet rule for MRSA or Pseudomonas. The CF Foundation reviewed the guideline in July 2024 and has an update in progress.

NCLEX tip 3: Burkholderia cepacia is the organism most critical to remember for infection control NCLEX questions. CF patients colonized with Bcc must never share a room, bathroom, waiting area, or equipment with other CF patients, and they need the strictest separation on the unit and in clinic. This is distinct from standard droplet precaution logic and tests higher-order infection control thinking.

Diagnostic testing and newborn screening

Newborn screening

Universal newborn screening for CF occurs in all 50 US states. The screening protocol:

1. Immunoreactive trypsinogen (IRT): Elevated IRT in a newborn’s dried blood spot (heel stick) indicates possible CF – blocked pancreatic ducts cause trypsinogen to leak into the bloodstream. IRT is a screening marker, not diagnostic.
2. DNA mutation analysis or repeat IRT: Most states test the same blood spot for a panel of CFTR variants when IRT is high (IRT/DNA); some repeat the IRT on a second specimen first (IRT/IRT/DNA). One or two variants identified = refer for sweat testing. Algorithms, cutoffs, and handling of very high IRT with no variants vary by state.
3. Confirmatory sweat chloride test: Required to confirm diagnosis regardless of genetic results.

NCLEX tip 4: The correct sequence for CF newborn screening is IRT first, then DNA mutation panel on the same or repeat specimen, then sweat chloride for confirmation. The sweat chloride test is the definitive diagnostic test – newborn screening identifies who needs the sweat chloride test, not the diagnosis itself.

Sweat chloride test

The sweat chloride test (pilocarpine iontophoresis) is the gold standard for CF diagnosis. Pilocarpine is applied to the forearm via mild electrical current to stimulate sweat production, which is then collected and analyzed.

• ≥60 mmol/L: Consistent with CF
• 30–59 mmol/L: Intermediate – repeat testing and extended CFTR genetic analysis required
• <30 mmol/L: CF unlikely

These cutoffs come from the 2017 CFF diagnosis consensus guidelines (mmol/L and mEq/L are numerically equivalent for chloride).

NCLEX tip 5: The diagnostic threshold for sweat chloride is ≥60 mEq/L – not just “elevated.” Values between 30 and 59 are borderline and require additional workup. This specific cutoff is frequently tested.

Nursing priorities and monitoring

Respiratory monitoring

• Oxygen saturation (SpO2): Target ≥90% at baseline; many patients with advanced disease have chronically lower saturations that they tolerate without supplemental oxygen. Baseline values must be established for each patient – do not apply population norms to CF patients with known baseline impairment.
• FEV1 percent predicted: The primary metric for tracking disease progression. A decline of ≥10% from personal best triggers evaluation for exacerbation. Transplant referral should occur no later than FEV1 <30% predicted, and earlier when decline is rapid or other markers of shortened survival are present.
• Sputum cultures: Track organism changes – new organisms (especially first Pseudomonas or Burkholderia) require prompt treatment and infection control review.
• Hemoptysis: Minor hemoptysis is common in CF (bronchiectatic vessels bleed easily). Massive hemoptysis (>240 mL/24 hours) is a medical emergency – hold airway clearance, position patient with bleeding side down, notify physician immediately.

Nutritional assessment

Undernutrition accelerates lung function decline in CF. The picture has shifted in the modulator era, though: the 2025 CFF Registry reports that 22% of children and 43% of adults with CF are now overweight or obese, so energy targets are individualized rather than automatically maximized. Every patient encounter should include:

• Weight and height (BMI percentile in children)
• Fat-soluble vitamin levels: retinol (A), 25-hydroxyvitamin D, alpha-tocopherol (E), prothrombin time/INR (K deficiency indicator)
• Assessment of PERT adherence and dosing adequacy
• Assessment of oral intake and appetite changes

Many CF patients require 110–200% of normal daily caloric requirements due to malabsorption, increased work of breathing, and chronic infection. For underweight patients, high-calorie, high-fat diets are appropriate; for patients on modulators who are gaining weight, the CF dietitian adjusts the target.

Mental health

CF is a progressive, life-limiting disease diagnosed in childhood. Depression and anxiety rates in the CF population are approximately two to three times higher than general population rates; the 2025 CFF Registry reports depression in 26% and anxiety in 29% of people with CF aged 12 and older. CFF/ECFS consensus recommends annual screening with the PHQ-9 and GAD-7 from age 12, and annual screening offered to at least one parent caregiver of children aged 0–17. Transitions of care – particularly from pediatric to adult CF programs – are high-risk periods for mental health deterioration.

Colorectal cancer screening

Adults with CF have a colorectal cancer risk 5–10 times that of the general population, rising to 25–30 times after organ transplant. CFF consensus recommends screening colonoscopy from age 40, repeated every 5 years (every 3 years after adenomas), with a CF-specific intensive bowel preparation. Transplant recipients start at age 30, within 2 years of transplant. Nurses preparing a patient for colonoscopy should expect a longer, more intensive prep than the standard regimen.

Pulmonary exacerbation monitoring table

Nutrition and pancreatic enzyme management

Lung transplantation

Indications

Cystic Fibrosis Foundation consensus guidelines (Ramos 2019) set staged triggers. For adults aged 18 and over, referral for transplant evaluation should happen no later than when any of these applies:

• FEV1 <30% predicted
• FEV1 <40% predicted with markers of shortened survival, such as more than two exacerbations a year needing IV antibiotics, massive hemoptysis (>240 mL) needing ICU admission or bronchial artery embolization, or pneumothorax
• FEV1 <50% predicted with rapid decline (>20% relative decline in 12 months)

Some markers trigger referral regardless of FEV1: 6-minute walk distance <400 m, hypoxemia at rest or with exertion, hypercarbia (PaCO2 >50 mmHg on arterial blood gas), pulmonary hypertension (PA systolic pressure >50 mmHg on echocardiogram, or right ventricular dysfunction), or an exacerbation that needed positive pressure ventilation. Children under 18 have their own, earlier thresholds (for example, referral by FEV1 <40% predicted).

The guidelines also recommend that the care team open the conversation about transplant as a future possibility once FEV1 drops below 50% predicted – well before referral is due.

Both lungs must be replaced – a single-lung transplant is not performed in CF because the remaining diseased CF lung would cross-contaminate the donor lung with Pseudomonas and other organisms.

Post-transplant CF considerations

NCLEX tip 6: CF does not recur in transplanted lungs. The donor lungs carry the donor’s CFTR genotype – they have functioning CFTR proteins. However, CF remains a systemic disease: the recipient’s sinuses, pancreas, GI tract, and sweat glands still have the CFTR mutation. Sinus care (such as saline rinses), PERT, CFRD management, and fat-soluble vitamin supplementation all continue post-transplant.

Patients colonized with Burkholderia cepacia complex – particularly B. cenocepacia – have significantly higher post-transplant mortality. The CFF referral guideline lists B. cenocepacia, B. gladioli, and B. dolosa among infections that may affect candidacy depending on center practice, so some centers decline these patients and others accept them. This is a critical consideration when counseling CF patients about infection control and cohorting compliance.

High-yield NCLEX tips

NCLEX tip 7: Sweat chloride diagnostic threshold Sweat chloride ≥60 mEq/L = diagnostic for CF. Values between 30 and 59 are borderline and require repeat testing plus genetic analysis. Values <30 mEq/L make CF unlikely. The specific threshold of 60 is the number to know.

NCLEX tip 8: Autosomal recessive inheritance CF is autosomal recessive. Both parents must carry at least one mutated CFTR allele. When two carriers have children, each pregnancy carries a 25% chance of CF, 50% chance of carrier status, 25% chance of normal genotype. A child with CF does not mean subsequent children will also have CF – each pregnancy is an independent event, so the 25% risk applies every time.

NCLEX tip 9: Airway clearance sequence The correct sequence for CF inhaled therapy is: (1) albuterol (bronchodilator – opens airways and prevents hypertonic-saline bronchospasm), (2) hypertonic saline and/or dornase alfa (thins the mucus), (3) airway clearance (vest, AD, ACBT, or percussion) performed while secretions are still thinned, (4) inhaled antibiotics (tobramycin, aztreonam) last, to maximize antibiotic delivery to cleared airways. Reversing this sequence reduces therapeutic effectiveness.

NCLEX tip 10: PERT with food Pancreatic enzyme replacement therapy is taken with the first bites of a meal or snack so the enzymes are in the stomach at the same time as the food. A patient who takes PERT before sitting down to eat or after finishing a meal is not getting full therapeutic benefit.

NCLEX tip 11: Burkholderia cepacia = strict segregation CF patients colonized with Burkholderia cepacia need the strictest separation from other CF patients – no shared waiting areas, room-to-room clinic flow or separate clinic days, and private hospital rooms away from other CF patients. B. cenocepacia in particular is associated with rapid lung function decline (“cepacia syndrome”) and post-transplant mortality. This is higher-stakes than standard droplet precaution scenarios.

NCLEX tip 12: CFRD treated with insulin only CF-related diabetes is treated with insulin. The CFF/ADA guideline does not recommend oral hypoglycemic agents (metformin, sulfonylureas, DPP-4 inhibitors) for CFRD. This is a key distinction from type 2 diabetes management – if an NCLEX question asks about CFRD management, insulin is always the correct answer for pharmacologic treatment.

NCLEX tip 13: Trikafta is not a cure Elexacaftor/tezacaftor/ivacaftor (Trikafta) improves CFTR function at the cellular level and produces dramatic clinical improvements for eligible patients. Eligibility now extends past the original “at least one ΔF508 allele” rule to any responsive variant, so check the current label rather than assuming a genotype rules a patient out. It is not a cure. Airway clearance, PERT, infection monitoring, and all other CF management continues. Patients who stop airway clearance after starting Trikafta are at risk for exacerbation.

NCLEX tip 14: Newborn screening sequence CF newborn screening uses IRT (immunoreactive trypsinogen) from a heel-stick blood spot as the initial screen. A positive IRT prompts DNA mutation analysis. Confirmatory diagnosis requires a sweat chloride test. The IRT elevation occurs because blocked pancreatic ducts cause trypsinogen to leak into the bloodstream – it is a consequence of EPI, not a direct measure of CFTR function.

NCLEX tip 15: Lung transplant – both lungs required In CF, bilateral sequential lung transplant is required – not single-lung. If only one CF lung is replaced, the remaining diseased lung’s chronic Pseudomonas colonization will contaminate the donor lung. Single-lung transplant is inappropriate in CF.

Summary: clinical priorities for CF nursing

Caring for a patient with CF requires simultaneous attention to respiratory, nutritional, endocrine, infectious, and psychosocial domains. Airway clearance is daily, lifelong, and non-negotiable. Nutrition is as critical as pulmonary function – underweight CF patients have faster FEV1 decline. CFTR modulators have transformed the disease trajectory for most patients, but require ongoing monitoring (LFTs, cataracts, drug interactions) and do not eliminate the need for standard CF care.

Infection control is a patient safety issue beyond the individual – CF patients who acquire Burkholderia cepacia from another CF patient face a fundamentally different disease trajectory. Strict cohorting policies protect every CF patient in a shared healthcare environment.

For a broader view of respiratory pharmacology covered in CF management, see pharmacology study guide and drug classifications. For end-stage respiratory failure context, see ARDS nursing.

Clinical content reviewed against the Cystic Fibrosis Foundation clinical care guidelines, the CFF Patient Registry 2025 highlights, current US prescribing information for all CFTR modulators (Trikafta and Alyftrek labels with the drug-induced liver injury boxed warning), and the peer-reviewed sources listed below. Last reviewed October 2026.

References

[1] Elborn JS – Cystic fibrosis, Lancet 2016;388(10059):2519–2531. doi:10.1016/S0140-6736(16)00576-6

[2] Flume PA, O’Sullivan BP, Robinson KA, et al. – Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health, Am J Respir Crit Care Med 2007;176(10):957–969. doi:10.1164/rccm.200705-664OC

[3] Ramsey BW, Davies J, McElvaney NG, et al. – A CFTR potentiator in patients with cystic fibrosis and the G551D mutation, N Engl J Med 2011;365(18):1663–1672. doi:10.1056/NEJMoa1105185

[4] Wainwright CE, Elborn JS, Ramsey BW, et al. – Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR, N Engl J Med 2015;373(3):220–231. doi:10.1056/NEJMoa1409547

[5] Middleton PG, Mall MA, Dřevínek P, et al. – Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele, N Engl J Med 2019;381(19):1809–1819. doi:10.1056/NEJMoa1908639

[6] Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. – Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health, Am J Respir Crit Care Med 2013;187(7):680–689. doi:10.1164/rccm.201207-1160oe

[7] Bell SC, Mall MA, Gutierrez H, et al. – The future of cystic fibrosis care: a global perspective, Lancet Respir Med 2020;8(1):65–124. doi:10.1016/S2213-2600(19)30337-6

[8] Castellani C, Cuppens H, Macek M Jr, et al. – Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice, J Cyst Fibros 2008;7(3):179–196. doi:10.1016/j.jcf.2008.03.009

[9] Moran A, Brunzell C, Cohen RC, et al. – Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, Diabetes Care 2010;33(12):2697–2708. doi:10.2337/dc10-1768

[10] Döring G, Flume P, Heijerman H, et al. – Treatment of lung infection in patients with cystic fibrosis: current and future strategies, J Cyst Fibros 2012;11(6):461–479. doi:10.1016/j.jcf.2012.10.004

[11] Flume PA, Mogayzel PJ Jr, Robinson KA, et al. – Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax, Am J Respir Crit Care Med 2010;182(3):298–306. doi:10.1164/rccm.201002-0157OC

[12] Graham BL, Steenbruggen I, Miller MR, et al. – Standardization of spirometry 2019 update: an official American Thoracic Society and European Respiratory Society technical statement, Am J Respir Crit Care Med 2019;200(8):e70–e88. doi:10.1164/rccm.201908-1590ST

[13] Stoltz DA, Meyerholz DK, Welsh MJ – Origins of cystic fibrosis lung disease, N Engl J Med 2015;372(4):351–362. doi:10.1056/NEJMra1300109

[14] Bhatt JM – Treatment of pulmonary exacerbations in cystic fibrosis, Eur Respir Rev 2013;22(129):205–216. doi:10.1183/09059180.00006512

[15] Ramos KJ, Smith PJ, McKone EF, et al. – Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines, J Cyst Fibros 2019;18(3):321–333. doi:10.1016/j.jcf.2019.03.002

[16] Cystic Fibrosis Foundation – 2025 Patient Registry Highlights. Bethesda, MD: Cystic Fibrosis Foundation; 2026. https://www.cff.org/medical-professionals/2025-patient-registry-highlights

[17] Ignatavicius DD, Rebar CR, Heimgartner NM – Medical-Surgical Nursing: Concepts for Clinical Judgment and Collaborative Care, 11th ed. Elsevier; 2024.

[18] Borowitz D, Robinson KA, Rosenfeld M, et al. – Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis, Journal of Pediatrics 2009;155(6 Suppl):S73–S93. doi:10.1016/j.jpeds.2009.09.001

[19] FitzSimmons SC, Burkhart GA, Borowitz D, et al. – High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis, New England Journal of Medicine 1997;336(18):1283–1289. doi:10.1056/NEJM199705013361803

[20] Vertex Pharmaceuticals – US FDA approval of ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class CFTR modulator, press release, December 20, 2024.

[21] Cystic Fibrosis Foundation – Mucus Thinners: recommended order of inhaled CF therapies. Bethesda, MD: Cystic Fibrosis Foundation.

[22] Saiman L, Siegel JD, LiPuma JJ, et al. – Infection prevention and control guideline for cystic fibrosis: 2013 update, Infect Control Hosp Epidemiol 2014;35(Suppl 1):S1–S67. doi:10.1086/676882

[23] Goss CH, Heltshe SL, West NE, et al. – A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment, Am J Respir Crit Care Med 2021;204(11):1295–1305. doi:10.1164/rccm.202102-0461OC

[24] Farrell PM, White TB, Ren CL, et al. – Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation, J Pediatr 2017;181S:S4–S15.e1. doi:10.1016/j.jpeds.2016.09.064

[25] Quittner AL, Abbott J, Georgiopoulos AM, et al. – International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety, Thorax 2016;71(1):26–34. doi:10.1136/thoraxjnl-2015-207488

[26] Cromwell EA, Ostrenga JS, Todd JV, et al. – Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020, J Cyst Fibros 2023;22(3):436–442. doi:10.1016/j.jcf.2023.02.009

[27] Hadjiliadis D, Khoruts A, Zauber AG, et al. – Cystic fibrosis colorectal cancer screening consensus recommendations, Gastroenterology 2018;154(3):736–745.e14. doi:10.1053/j.gastro.2017.12.012

[28] Vertex Pharmaceuticals – TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor tablets; ivacaftor tablets) US prescribing information, including boxed warning for drug-induced liver injury and liver failure; revised March 2026. DailyMed setid f354423a-85c2-41c3-a9db-0f3aee135d8d.

[29] Vertex Pharmaceuticals – ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor tablets) US prescribing information, including boxed warning for drug-induced liver injury and liver failure; revised March 2026. DailyMed setid 7e635909-c6fd-4f0d-ae77-cdff03653a20.

[30] Vertex Pharmaceuticals – KALYDECO (ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and SYMDEKO (tezacaftor/ivacaftor) US prescribing information, revised March 2026 (intracranial hypertension and neuropsychiatric events warnings). DailyMed.

[31] Sathe M, Houwen R – Meconium ileus in cystic fibrosis, J Cyst Fibros 2017;16(Suppl 2):S32–S39. doi:10.1016/j.jcf.2017.06.007

[32] Centers for Disease Control and Prevention – Appendix A: type and duration of precautions recommended for selected infections and conditions, Guideline for Isolation Precautions, updated September 11, 2026. https://www.cdc.gov/infection-control/hcp/isolation-precautions/appendix-a-type-duration.html

[33] Cystic Fibrosis Foundation – Infection Prevention and Control Clinical Care Guidelines (executive summary of Saiman 2014; reviewed July 2024, update in progress). https://www.cff.org/medical-professionals/infection-prevention-and-control-clinical-care-guidelines

[34] Haworth CS, Banks J, Capstick T, et al. – British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD), Thorax 2017;72(Suppl 2):ii1–ii64. doi:10.1136/thoraxjnl-2017-210927